Skip to main content

Beyond Genomics Changes Name to BG Medicine, Pursues Drug-Development Applications

NEW YORK, Feb. 4 (GenomeWeb News) - Shifting its focus, Beyond Genomics has changed its name to BG Medicine and will now pursue the drug-development applications of its systems pharmacology platform, the company said yesterday.


As part of the realignment, the company appointed Pieter Muntendam as its new president, the statement said. Muntendam most recently led the Biopharmaceutical and Healthcare division of NetNumina, an informatics services company, the statement added.


According to BG, its systems pharmacology platform integrates metabolite, protein, and gene transcript profiling to "characterize the molecular changes due to disease or drug effects." The company's goal will be to "improve upon leading drug classes, identify new indications, and explore novel drug combinations," Muntendam said.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.